Does the route matter? A preclinical review of mesenchymal stromal cell delivery to the kidney

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Abstract

Mesenchymal stromal/stem cell (MSC) therapy has been thoroughly tested in preclinical animal models and holds great promise for the treatment of kidney diseases. It is becoming increasingly evident that the efficacy of MSC therapy is dependent on several factors including dosage, the tissue source of MSCs, the route of delivery and timing of administration. In a time where MSC therapy is moving from preclinical research to clinically therapeutic use, the importance of choice of delivery method, modality, and administration route increases. In this review, we provide an overview of the different MSC delivery routes used in preclinical kidney disease models, highlight the recent advances in the field, and summarize studies comparing delivery routes of MSCs to the kidney.

OriginalsprogEngelsk
TidsskriftAPMIS - Journal of Pathology, Microbiology and Immunology
Vol/bind131
Nummer12
Sider (fra-til)687-697
Antal sider11
ISSN0903-4641
DOI
StatusUdgivet - dec. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Does the route matter? A preclinical review of mesenchymal stromal cell delivery to the kidney'. Sammen danner de et unikt fingeraftryk.

Citationsformater